92 results on '"Zelniker, Thomas A."'
Search Results
2. A Novel Approach to Continuous Heart Rhythm Monitoring for Arrhythmia Detection
3. Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide
4. Editorial: Exploring modern approaches to address critical care challenges in risk stratification for cardiology
5. Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome
6. Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials
7. A novel prediction model for pulmonary embolism: from dichotomizing algorithms to personalized likelihood
8. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
9. Interruption of viral interference by anti-SARS-CoV-2 vaccination
10. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
11. Mid-regional pro-adrenomedullin and lactate levels for risk stratification in patients with out-of-hospital cardiac arrest
12. Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery
13. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
14. Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria
15. SGLT2 inhibitors in heart failure: insights from plasma proteomics
16. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction
17. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial
18. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
19. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial
20. Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial
21. Positionspapier Herzinsuffizienz und Diabetes
22. Positionspapier Herzinsuffizienz und Diabetes
23. Relationship of diabetes, heart failure, and N‐terminal pro‐B‐type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation
24. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention
25. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
26. Comparison of the Prevalence of SARS-CoV-2 Nucleoprotein Antibodies in Healthcare Workers and an Unselected Adult and Pediatric All-Comer Patient Population in Austria
27. Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation
28. Abstract 13729: Monotherapy With a P2Y12 Inhibitor versus Aspirin for Secondary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) Events: A Meta-Analysis of Randomized Trials
29. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
30. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
31. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
32. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
33. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
34. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
35. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
36. Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation
37. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
38. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes
39. Relationship between markers of inflammation and hemodynamic stress and death in patients with out-of-hospital cardiac arrest
40. BIOMARKER PREDICTION OF MAJOR CORONARY EVENTS AND COMPLEX REVASCULARIZATION PROCEDURES IN PATIENTS WITH STABLE ATHEROSCLEROSIS
41. Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36
42. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
43. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization
44. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58
45. Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial
46. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58
47. Abstract 16688: Effects of Evolocumab in Patients With Prior Percutaneous Coronary Intervention: An Analysis From the Fourier Trial
48. Serum neprilysin and the risk of death in patients with out-of-hospital cardiac arrest of non-traumatic origin
49. Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trials
50. Feasibility of CardioSecur®, a Mobile 4-Electrode/22-Lead ECG Device, in the Prehospital Emergency Setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.